TGA warns of CV risk with osteoporosis drug
Professor Roderick Clifton-Bligh said a ‘cautious approach’ was needed in patients with prior MI or stroke.
Doctors are being warned against prescribing romosozumab in patients with a history of MI or stroke following a TGA investigation into the cardiovascular risks of the potent osteoporosis drug.
The product information (PI) for romosozumab (Evenity) has been updated to include a special warning for prescribers to consider a patient’s fracture and cardiovascular risks in tandem.
